Differential Study of Invasive Pituitary Adenomas in the Sellar and Cavernous Sinus Regions

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This study involves collecting paired tumor samples from intrasellar and cavernous sinus regions of 20 invasive pituitary tumor patients, preserving them at -80°C for quality multi-omics analysis. Proteomics and transcriptomics are employed to identify molecular differences, while imaging data (MRI/CT) assesses tumor morphology and invasion. In vitro experiments and mechanistic studies validate key findings, exploring how regional molecular differences affect tumor behavior. Data integration combines multi-omics and imaging features to uncover biomarkers and pathways associated with invasiveness and regional specificity, with statistical analysis ensuring significance and reliability.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Invasive pituitary tumors involving the cavernous sinus

• Retrospective inclusion of patients who have signed informed consent forms for the donation of biological samples and health-related information

• Age range: 18-80 years

• Subjects are willing to participate in this study

Locations
Other Locations
China
Zhongshan Hospital Fudan University
RECRUITING
Shanghai
Contact Information
Primary
Tao Xie
xie.tao@zs-hospital.sh.cn
+8613524281211
Time Frame
Start Date: 2024-11-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 20
Treatments
pituitary tumors in cavernous sinus group
The 20 pituitary tumor samples in this group were obtained from the cavernous sinus region removed during surgery and were paired with pituitary tumors in the intralellar region
pituitary tumors in sellar group
The 20 pituitary tumors in this group were obtained from intrasellar samples removed during surgery and were paired with pituitary tumors in the cavernous sinus region
Sponsors
Leads: Shanghai Zhongshan Hospital

This content was sourced from clinicaltrials.gov